Clinical implementation of targeted and immunotherapies for advanced RCC

Episode 1 December 14, 2022 00:19:51
Clinical implementation of targeted and immunotherapies for advanced RCC
COR2ED Medical Education
Clinical implementation of targeted and immunotherapies for advanced RCC

Dec 14 2022 | 00:19:51

/

Show Notes

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of Brest and Quimper in France, discuss the clinical implementation of targeted and immunotherapies for advanced renal cell carcinoma (RCC).

In this podcast, the two experts discuss data from key trials CHECKMATE 214 (ipilimumab and nivolumab), KEYNOTE 426 (axitinib and pembrolizumab), CHECKMATE 9ER (cabozantinib and nivolumab), CLEAR (Lenvatinib and pembrolizumab) and COSMIC 313 (cabozantinib plus nivolumab and ipilimumab) and the implications for clinical practice.

They also discuss management of toxicities associated with combination treatments, including dosing strategies to ensure the patient remains on optimal treatment and improved education for patients and clinicians so that they recognise side effects and how to manage them.

Other Episodes

Episode 0

December 02, 2021 00:29:56
Episode Cover

VEGFR-TKIs alone or in combination with immune checkpoint inhibitors in clinical practice for the treatment of HCC

In this medical education podcast episode, Prof. Peter Galle and Prof. Amit Singal discuss the use of VEGFR-TKIs in the treatment of advanced or...

Listen

Episode 12

April 26, 2023 00:21:09
Episode Cover

Treatment sequencing in advanced mCRC patients

COR2ED Medical Education: This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond.  Dr Shubham Pant from...

Listen

Episode 1

July 05, 2022 00:21:56
Episode Cover

Timing of ARSI and taxanes for mCSPC

COR2ED Medical Education: Dr. Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr. Neal Shore, Uro-Oncologist and Chief...

Listen